CHRONIC LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET ANALYSIS

Chronic Lymphocytic Leukemia Therapeutics Market, by Drug (Idelalisib (Zydelig), Venetoclax (Venclexta), Ibrutinib (Imbruvica), Ofatumumab (Arzerra), Fludarabine (Fludara), Obinutuzumab (Gazyva), Bendamustine Hydrochloride (Treanda), and Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa ) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI2049
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Chronic Lymphocytic Leukemia Therapeutics Market – Regional Analysis

On the basis of region, the chronic lymphocytic leukemia therapeutics market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America accounted for the largest market share in 2016 due to the presence of breakthrough pipeline drugs. For instance, the drug Acalabrutinib—manufactured by Acerta Pharma BV—is under phase 2 clinical trial for the treatment of CLL and small lymphocytic lymphoma (SLL) and the study is expected to complete in January 2019

Increasing research activities along with increasing prevalence of CLL in US expected to propel the growth of CLL in North America. According to the Leukemia & Lymphoma Society, US, there are 119,386 patients in 2013 which has been increased to 15,720 in 2014.